Diabetes Care, Vol 21, Issue 9 1445-1450, Copyright © 1998 by American Diabetes Association

ARTICLES

Two-step islet autoantibody screening for risk assessment of type 1 diabetes in relatives

MR Pastore, E Bazzigaluppi, R Bonfanti, N Dozio, A Sergi, A Balini, C Belloni, F Meschi, E Bonifacio and E Bosi
Department of Internal Medicine, Istituto Scientifico Ospedale San Raffaele, University of Milan, Italy.

OBJECTIVE: To examine the performance of islet cell antibodies (ICAs) and antibodies to glutamate decarboxylase (GADA), IA-2 (IA-2 antibody [IA-2A]), and insulin (insulin autoantibody [IAA]), alone and in combination, in assessing type 1 diabetes risk within type 1 diabetic families to identify a practical and effective screening strategy for predicting type 1 diabetes in relatives. RESEARCH DESIGN AND METHODS: ICA, GADA, IA-2A, and IAA were determined in 806 first-degree relatives participating in a prospective type 1 diabetes family study (median follow-up 6.17 years, range 0.6-8.3). The conferred risk of developing type 1 diabetes within 6 years was evaluated by Kaplan-Meier for each antibody marker, used alone or in combination. RESULTS: ICAs were detected in 3%, GADA in 5.1%, IA-2A in 2.5%, and IAA in 3.7% of relatives; > or =1 antibody markers were detected in 10.7% of relatives and > or =2 were detected in 1.9% of relatives. The risk of type 1 diabetes at 6 years was 1.5% in relatives with only 1 marker and 24.8% in relatives with > or =2 markers. As a practical and effective strategy for type 1 diabetes risk assessment in relatives, this study indicates a first-step screening based on GADA and IA-2A measurement--which identified 6.5% of relatives, including all who developed the disease, with a 6-year type 1 diabetes risk of 9.0%--followed by a second step based on ICA and IAA measurement in relatives with either GADA or IA-2A, which identified a total of 1.9% of all relatives as having > or =2 markers, and a 6-year risk of 24.8%, including 6 of 7 who developed type 1 diabetes. CONCLUSIONS: A two-step antibody screening, based first on GADA and IA-2A and then on ICA and IAA measurements in identified individuals, is likely to be a practical, sensitive, and effective strategy for predicting type 1 diabetes in first-degree relatives.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. P. Krischer, D. D. Cuthbertson, L. Yu, T. Orban, N. Maclaren, R. Jackson, W. E. Winter, D. A. Schatz, J. P. Palmer, and G. S. Eisenbarth Screening Strategies for the Identification of Multiple Antibody-Positive Relatives of Individuals with Type 1 Diabetes J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 103 - 108. [Abstract] [Full Text] [PDF]

				M.-R. Pastore, E. Bazzigaluppi, C. Belloni, C. Arcovio, E. Bonifacio, and E. Bosi Six Months of Gluten-Free Diet Do Not Influence Autoantibody Titers, but Improve Insulin Secretion in Subjects at High Risk for Type 1 Diabetes J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 162 - 165. [Abstract] [Full Text] [PDF]

				W. E. Winter, N. Harris, and D. Schatz Immunological Markers in the Diagnosis and Prediction of Autoimmune Type 1a Diabetes Clin. Diabetes, October 1, 2002; 20(4): 183 - 191. [Abstract] [Full Text] [PDF]

				R. Lorini, A. Alibrandi, L. Vitali, C. Klersy, M. Martinetti, C. Betterle, G. d'Annunzio, and E. Bonifacio Risk of Type 1 Diabetes Development in Children With Incidental Hyperglycemia: A multicenter Italian study Diabetes Care, July 1, 2001; 24(7): 1210 - 1216. [Abstract] [Full Text] [PDF]

				L. Ward, J. Paquette, E. Seidman, C. Huot, F. Alvarez, P. Crock, E. Delvin, O. Kämpe, and C. Deal Severe Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy in an Adolescent Girl with a Novel AIRE Mutation: Response to Immunosuppressive Therapy J. Clin. Endocrinol. Metab., March 1, 1999; 84(3): 844 - 852. [Abstract] [Full Text]